Format

Send to

Choose Destination
Clin Cancer Res. 2016 Oct 15;22(20):4963-4965. Epub 2016 Aug 12.

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?

Author information

1
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
2
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. davidsonne@upmc.edu.

Abstract

The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor-positive lymph node-negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays. Clin Cancer Res; 22(20); 4963-5. ©2016 AACRSee related article by Sestak et al., p. 5043.

PMID:
27521446
PMCID:
PMC5154749
DOI:
10.1158/1078-0432.CCR-16-1513
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center